Overview

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Clinical Trials in Organ Transplantation
Treatments:
Antilymphocyte Serum
Calcineurin Inhibitors
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Tacrolimus
Thymoglobulin